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INTRODUCTION 
Secretome is a factor found in the stem cell 
culture medium. This factor may repair the tissues 
of the organs that were damaged by various 
degenerative disorders1. A previous study has 
reported that secretome derived from the fetal 
human umbilical cord mesenchymal stem cell 
(HUC-MSC) may be an effective regenerative agent 
for β-cell pancreatic regeneration in Type 1 
diabetes mellitus and for skin regeneration in 
incisional and burn wound healing. 
The administration of cisplatin as a 
chemotherapeutic agent is limited because it 
causes side effects, such as reproductive toxicity 
and progresses to testicular dysfunction2. As a 
degenerative disorder, testicular dysfunction is 
characterized by failure in the synthesis of 
reproductive hormones and spermatogenesis. 
Cisplatin-induced testicular cell damage would 
promote vimentin and cytokeratin localization in 
the spermatogenic, Sertoli, and Leydig cells. 
Studies on the use of secretome in 
promoting the recovery of various degenerative 
disorders and its effects on the spermatogenesis of 
rats with cisplatin-induced testicular dysfunction 
have not been conducted. The aim of this stud was 
to investigate the effect of secretome derived from 
HUC-MSC on cisplatin-induced testicular 
dysfunction in rats. 
 
MATERIALS AND METHODS 
 Thirty-six male Wistar rats were adapted 
for 7 days before the administration of cisplatin, 
and these rats were fed with basal food and water 
ad libitum and were divided into the control and 
secretome-treated groups. Testicular dysfunction 
was induced by cisplatin at the dose 3 mg/kg BW3 
intraperitoneally 3 times with 3 days’ interval. 
 The secretome-treated group was further 
divided into the low- and high-dose secretome-
treated group. Secretomes were injected 
intraperitoneally once a week for 4 weeks at a dose 
of 0.2 and 0.5 mL/kg BW in the low- and high-dose 
secretome-treated groups, respectively. The rats 
were sacrificed every 1 week after the injection of 
secretome, and the cauda epididymis of the rat was 
collected then processed by paraffin method for 
immunohistochemistry staining by using vimentin 
and cytokeratin primary antibody. The result were 
analyzed descriptively. 
 
RESULT AND DISCUSSION  
 1 week after the first secretome injection, 
the vimentin immunoreactivity of the low-dose 
group was weak in the spermatogonia, moderate in 
the primary spermatocytes and strong in the sper-
matozoa and Sertoli cells (Figure 1A1). In the high-
dose group, vimentin immunoreactivity was weak 
in the primary spermatocytes and moderate in the 
spermatid and Sertoli cells (Figure 1A2). Vimentin 
immunoreactivity was not observed in the Leydig 
cells of the two groups. 1 week after the second 
secretome injection in the low-dose group, 
vimentin immunoreactivity was weak in the 
spermatogonia, moderate in the primary 
spermatocytes and strong in the spermatozoa, 
Sertoli cells, and Leydig cells (Figure 1B1). 
Meanwhile, in the high-dose group, vimentin 
immunoreactivity in the spermatogonia and Leydig 
cells, spermatocytes, and spermatozoa and Sertoli 
cells was strong, moderate, and extremely strong, 
respectively (Figure 1B2). 1 week after the third 
secretome injection in the low-dose group, 
vimentin immunoreactivity in the primary 
spermatocytes and Leydig cells and spermatozoa 
and Sertoli cells were weak and moderate, 
respectively. However, vimentin immunoreactivity 
was not observed in the spermatogonia (Figure 
1C1). In the high-dose group, vimentin 
immunoreactivity was weak in the spermatogonia 
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and primary spermatocytes. It was moderate in the 
Leydig cells and strong in the spermatozoa and 
Sertoli cells (Figure 1C2). After the last secretome 
injection, vimentin immunoreactivity in the 
primary spermatocyte and Leydig cells was weak, 
and that in the spermatozoa and Sertoli cells was 
moderate. However, it was not observed in the 
spermatogonia (Figure 1D1). 
 
 
Figure 1. Vimentin immunoreactivity after 
secretome injection (immunohistochemistry; 500× 
magnification). In the low-dose group (A1), 1 week 
after the first secretome injection, a strong 
vimentin immunoreactivity was observed in the 
spermatozoa (yellow arrow) and Sertoli cells (blue 
arrow), whereas in the high-dose (A2) group, the 
immunoreactivity was moderate. In the low-dose 
group (B1), 1 week after the second secretome 
injection, a strong vimentin immunoreactivity was 
still observed in the spermatozoa and Sertoli cells. 
Meanwhile, in the high-dose group (B2), the 
immunoreactivity was very strong in the same cell. 
In the low-dose group (C1), 1 week after the third 
secretome injection, moderate vimentin 
immunoreactivity was observed in the 
spermatozoa and Sertoli cells, whereas in the high-
dose group (C2), the immunoreactivity was strong 
in the same cells. Then, 1 week after the last 
injection in the high-dose group (D1), the vimentin 
immunoreactivity was moderate in the 
spermatozoa and Sertoli cells. Spermatogonia (red 
arrow), primary spermatocytes (green arrow), and 
Leydig cells (white arrow). 
 
 1 week after the first secretome injection 
in the low-dose group, cytokeratin immunoreactiv-
ity was weak in the spermatozoa and Sertoli cells. 
(Figure 2A1). Meanwhile, in the high-dose group, 
cytokeratin immunoreactivity was weak in the 
spermatozoa, Sertoli cells, and Leydig cells (Figur 
2A2). 1 week after the second secretome injection 
in the low-dose group, cytokeratin 
immunoreactivity was moderate in the 
spermatogonia, primary spermatocytes, 
spermatozoa, and Sertoli cells, and it was strong in 
the Leydig cells (Figure 2B1). In the high-dose 
group, cytokeratin immunoreactivity was weak in 
the spermatogonia and primary spermatocytes. 
Meanwhile, cytokeratin immunoreactivity was 
moderate in the spermatozoa and Sertoli cells and 
very strong in the Leydig cells (Figure 2B2). 1 week 
after the third secretome injection in the low-dose 
group, cytokeratin immunoreactivity was weak in 
the spermatogonia, primary spermatocytes, 
spermatozoa, and Leydig cells. However, it was 
moderate in the Sertoli cells (Figure 2C1). In the 
high-dose group, cytokeratin immunoreactivity 
was moderate in the spermatogonia and 
spermatozoa and strong in the Sertoli and Leydig 
cells (Figure 2C2). 1 week after the last secretome 
injection in the high-dose group, cytokeratin 
immunoreactivity was weak in the primary 
spermatocytes, moderate in the spermatogonia 
and strong in the spermatozoa, Sertoli cells, and 
Leydig cells (Figure 2D1). 
 Testicular toxicity is one of the serious 
side effects of cisplatin, which is used in 
chemotherapy, which causes loss of 
spermatogonia4, abnormalities in the Leydig cells, 
and suppression of testosterone production2,4. 
Cisplatin-induced testicular cell damage is caused 
by oxidative stress, which induces cellular damage 
by the generation of reactive oxygen species2. In 
the present study, the regenerative effect of 
secretome is characterized by the presence of sper-
matogenesis. 
Vimentin and cytokeratin, which are 
intermediate filaments, were observed in this 
present study. Vimentin distribution depends on 
the spermatogenesis cycle, and they would be 
distributed along with the head of the sper-
matozoa. Vimentin would maintain the integrity of 
the spermatogenic cells and their connection. 
Another study has reported that vimentin was also 
found in the Leydig cells of mature or immature 
testes. Vimentin was observed in the 
spermatogenic, Sertoli, and Leydig cells because 
vimentin supported and controlled the cell 
structure and function of fetuses or adults5. Very 
strong vimentin immunoreactivity indicated a 
regenerative process. 
Cytokeratin was found in the Sertoli cells 
during the development stage only. Secretome that 
contains growth factors and cytokines, which are 
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regenerative agents, might play a role in the 
formation of cytokeratin in adult rats with 
cisplatin-induced testicular dysfunction. The 
dynamic increase and decrease in the 
immunoreactivity of vimentin and cytokeratin 
might be caused by high inflammation reaction by 
endogenous cytokines. The use of secretome in 
diabetic rat could repair β-cells of the treatment 
which is provided earlier. However, it could not 
maintain the β-cells if the treatment is provided 
later. It was suggested that exogenous tumor 
necrosis factor-α and interleukin (IL) in secretome 
would stimulate severe inflammation reaction6. 
 
 
Figure 2. Cytokeratin immunoreactivity after 
secretome injection (immunohistochemistry; 500× 
magnification). In the low-dose group (A1), 1 week 
after the first secretome injection, a weak 
cytokeratin immunoreactivity was observed in the 
spermatozoa (yellow arrow), whereas in the high-
dose group (A2), the immunoreactivity was weak 
in all spermatogenic cells, Sertoli cells (blue 
arrow), and Leydig cells (white arrow). In the low-
dose group (B1), 1 week after the second 
secretome injection, a strong cytokeratin 
immunoreactivity was observed in the Leydig cells, 
whereas in the high-dose group (B2), very strong 
immunoreactivity was noted in the Leydig cells. In 
the low-dose group (C1), 1 week after the third 
secretome injection, moderate cytokeratin 
immunoreactivity was observed in the 
spermatozoa and Sertoli cells, whereas in the high-
dose group (C2), a strong immunoreactivity was 
found in the Sertoli and Leydig cells. Then, 1 week 
after the last injection, the high-dose group (D1) 
showed a strong cytokeratin immunoreactivity in 
the spermatozoa and Sertoli and Leydig cells. 
 
Severe inflammation might inhibit 
vimentin and cytokeratin formation. In normal 
conditions, Leydig cells might secrete cytokines, 
such as IL-1 and IL-6. Macrophages were present in 
the testicular interstitium, and they may stimulate 
Leydig cells to produce cytokines. An in vitro study 
has reported that IL-1 and IL-6 also influenced the 
Sertoli cells7. However, the structures of the sem-
iniferous tubules and cell morphology were 
normal. 
 
CONCLUSION 
Secretome injections were effective 1 
week after the second secretome injection that was 
administered at the high dose. That is, the 
immunoreactivity of vimentin and cytokeratin was 
very strong. However, secretome could promote 
the regeneration of seminiferous tubules based on 
cytoskeletal protein profile in both the groups. 
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